[Treatment of hematologic neoplasms during pregnancy].
The most common hematological malignancy in pregnant patients is Hodgkin's lymphoma, but other diseases such as chronic and acute leukemia or non Hodgkin's lymphoma have also been reported. In the last decade, new drugs have changed the prognostic of acute promyelocytic leukemia, chronic myeloid leukemia and non Hodgkin's lymphoma. Herein we present updated information on drugs and treatments, new developments, mechanism of action, clinical application, experience on treatment outcomes, adverse effects and teratogenesis, with the objective of orienting hematologists, oncologists and pediatricians. The medical team should offer the most efficient treatment available in order to achieve cure or remission of the disease, and also inform on possible risks for the mother and the fetus, as well as those derived from the delay in treatment application.
Tartas
Norma E
NE
Departamento de Hematología, Instituto Alexander Fleming, Buenos Aires, Argentina. ntartas@interar.com.ar
Foncuberta
María C
MC
Avalos
Julio C Sánchez
JC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000069283:Rituximab; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases